The diagnostic value of miR-338-3p in acute coronary syndrome and its correlation with MACE occurrence

Acute coronary syndrome (ACS) is a severe form of coronary heart disease. Therefore, identifying biomarkers that can be used for large-scale screening to enable early intervention in ACS is beneficial for avoiding adverse outcomes. This study included 119 ACS patients, 97 stable angina pectoris (SAP) patients, and 89 healthy controls. The serum level of miR-338-3p was detected using qRT-PCR. The diagnostic potential was analyzed via ROC, and the association with the severity of ACS was investigated using the Pearson method. The assessment of risk factors for major adverse cardiovascular events (MACE) in ACS patients was conducted using multivariate logistic regression, and the interaction between miR-338-3p and THBS1 was evaluated using dual-luciferase reporter and RNA immunoprecipitation (RIP) assays. In comparison with the healthy control group, the expression level of miR-338-3p was downregulated in patients with ACS, and it demonstrated a negative correlation with CK-MB, cTnI, and the Gensini score. miR-338-3p exhibits significant diagnostic efficacy in distinguishing ACS patients from healthy individuals (AUC = 0.948). Furthermore, it has been confirmed that miR-338-3p, cTnI, and the Gensini score are effective indicators for predicting the occurrence of MACE in ACS patients. The targeting of THBS1 by miR-338-3p was confirmed by dual-luciferase and RIP assays. Notably, the expression of THBS1 was significantly upregulated in ACS patients. This study found that the expression of miR-338-3p is reduced in ACS patients, and its abnormal expression may serve as a predictive marker for ACS and MACE.